| Name of study |
Programa de Investigación de Factores de Riesgo de Enfermedad Cardiovascular (PIFRECV) |
| Inclusion criteria |
Study participants were recruited in 2005 by the 'Programa de Investigación de Factores de Riesgo de Enfermedad Cardiovascular' (PIFRECV); participants had to have an FPG 5.6–6.9 mmol/L |
| Exclusion criteria |
Diabetes, individuals on corticosteroid treatment, pregnant women, individuals with cardiovascular complications |
| Notes |
Most baseline data for cohort becoming diabetic at follow‐up (N = 94 with IFG) |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Study participation: description of source population or population of interest |
Low risk |
Yes |
| Study participation: description of glycaemic status at baseline |
Low risk |
Yes |
| Study participation: adequate description of sampling frame & recruitment |
Low risk |
Yes |
| Study participation: adequate description of period & recruitment place |
Low risk |
Yes |
| Study participation: adequate description of inclusion & exclusion criteria |
Low risk |
Inclusion and exclusion criteria described |
| Study attrition: description of attempts to collect information on participants who dropped out |
Low risk |
Yes |
| Study attrition: reasons for loss to follow‐up provided |
Low risk |
Yes |
| Study attrition: adequate description of participants lost to follow‐up |
Unclear risk |
Scarce data |
| Study attrition: no important differences between participants who completed the study and those who did not |
Unclear risk |
Not reported |
| Glycaemic status measurement: provision of clear definition or description of glycaemic status |
Low risk |
Yes |
| Glycaemic status measurement: valid and reliable method of glycaemic status measurement |
Low risk |
Yes |
| Glycaemic status measurement: continuous variables reported or appropriate cut points used |
Low risk |
IFG: 5.6–7.0 (low range: 5.6–6.1; high range: 6.1–6.9) |
| Glycaemic status measurement: same method and setting of measurement of the glycaemic status for all study participants |
Low risk |
Yes |
| Outcome measurement: clear definition of the outcome provided |
Low risk |
FPG ≥ 7.0 (on 2 consecutive days); HbA1c ≥ 6.5 |
| Outcome measurement: method of outcome measurement used valid & reliable |
Low risk |
Yes |
| Outcome measurement: same method & setting of outcome measurement for all study participants |
Low risk |
Yes |
| Study confounding: important confounders measured |
Unclear risk |
Some covariates were measured (see Appendix 16 and Appendix 17) |
| Study confounding: clear definitions of important confounders provided |
Low risk |
Yes |
| Study confounding: measurement of confounders valid & reliable |
Low risk |
Yes |
| Study confounding: same method & setting for measurements of confounders for all study participants |
Low risk |
Yes |
| Study confounding: appropriate methods used if missing confounder data imputed |
Unclear risk |
Not reported |
| Study confounding: important potential confounders accounted for in study design |
Unclear risk |
Some covariates planned (see Appendix 16 and Appendix 17) |
| Study confounding: important potential confounders accounted for in the analysis |
Unclear risk |
Some covariates analysed (see Appendix 16 and Appendix 17) |
| Statistical analysis & reporting: sufficient presentation of data to assess adequacy of the analytic strategy |
Low risk |
Cumulative incidence, odds ratio |
| Statistical analysis & reporting: the statistical model is adequate for the design of the study |
Low risk |
Cox regression analysis (comparing 'high range' glycaemia (> 6.1 mmol/L) with 'low range' glycaemia (< 6.1 mmol/L) |
